Wells Fargo analyst Derek Archila raised the firm's price target on Disc Medicine to $79 from $78 and keeps an Overweight rating on the shares. The firm believes there is a good chance Disc Medicine can resolve bitopertin's complete response letter with the ongoing Phase 3 APOLLO trial and that the outcome of the upcoming Type A meeting will provide that clarity. Wells is positively biased into the update which is likely in mid-to-late April.
